婴儿发病的帕金森症,动力障碍和发育迟缓:不要忘记多重胺的缺陷!
Heidy Baide-Mairena1,2, Arthur Coget3, Nicolas Leboucq3
1Département de Neuropédiatrie, Hôpital Gui de Chauliac, Montpellier, France.
Annals of clinical and translational neurology
|July 26, 2023
概括
这项研究详细介绍了一名患有大量ATN1 CAG扩张的婴儿,出现严重的发育迟缓和帕金森症,导致致命的结局. 它强调了在婴儿神经退行性疾病中考虑多重胺扩张障碍的重要性.
科学领域:
- 遗传学 是一个遗传学.
- 神经学 神经学
- 儿科 儿科 儿科
背景情况:
- 牙骨-骨缩性缩 (DRPLA) 是一种罕见的神经退行性疾病.
- 聚聚胺扩张障碍通常与成人发作的神经症状有关.
- 婴儿发作的DRPLA异常罕见,并且经常表现出异常症状.
研究的目的:
- 描述具有最大报告ATN1 CAG扩张的婴儿的临床和分子表型.
- 要突出婴儿发作的DRPLA的表现,包括帕金森症.
- 强调在婴儿神经退行性疾病中考虑多重胺扩张缺陷.
主要方法:
- 婴儿发育迟缓和神经系统恶化的临床病例介绍.
- 大脑MRI用于评估大脑异常.
- 死后分子分析以确认遗传诊断.
主要成果:
- 婴儿呈现出大量的ATN1 CAG扩张 (98次重复).
- 临床特征包括发育迟缓,小头,发育不良, dystonia-parkinsonism 和动力障碍.
- 大脑MRI显示了球体的强度过高和大脑缩.
- 分子分析证实了DRPLA,死后诊断.
结论:
- 婴儿开始的DRPLA可以出现帕金森症和严重的神经退行症.
- 大量的ATN1 CAG扩张可以导致严重的,早期发作的神经退行性疾病.
- 在婴儿神经退行性疾病的差异诊断中,应考虑多重胺扩张障碍.
更多相关视频
10:41Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia
Published on: September 12, 2020
7.4K
05:52Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis
Published on: November 21, 2013
15.0K
相关概念视频
Parkinson's Disease: Overview
599
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
599
Parkinson's Disease: Treatment
301
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
301
Inborn Errors of Metabolism
199
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
199
Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
Overview of Protein Metabolism
1.3K
Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
1.3K
Antiepileptic Drugs: Potassium Channel Activators
214
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
214
